What is the appropriate evaluation and initial management for a female patient who woke up with diffuse joint pain, stiffness, limited range of motion, and joint swelling?

Evaluation and Management of Acute Polyarticular Joint Pain with Swelling and Stiffness

This patient requires urgent rheumatology referral within 6 weeks of symptom onset, immediate laboratory evaluation including RF, anti-CCP, ESR, CRP, and CBC, and should be started on NSAIDs for symptomatic relief while awaiting specialist assessment. 1, 2

Immediate Assessment Priorities

Rule Out Septic Arthritis First

• If any single joint shows fever, severe pain, erythema, and warmth, perform immediate joint aspiration before any other workup, as septic arthritis is a surgical emergency 2
• Send aspirated fluid for Gram stain, bacterial culture, cell count with differential, and crystal analysis 2
• However, polyarticular presentation with symmetric involvement makes septic arthritis less likely 3

Confirm True Inflammatory Arthritis

• Joint swelling accompanied by pain or stiffness defines true arthritis and distinguishes it from cellulitis, bursitis, or soft-tissue problems 2
• Perform the "squeeze test" on metacarpophalangeal (MCP) and metatarsophalangeal (MTP) joints to detect small-joint involvement 2
• Morning stiffness lasting longer than 30 minutes strongly suggests inflammatory arthritis rather than mechanical or degenerative causes 2
• Palpate for synovial thickening and warmth; inflammatory synovitis feels boggy and warm, whereas osteoarthritis shows bony hypertrophy and crepitus 4

Essential Laboratory Workup (Order Immediately)

Serologic Testing

• Measure rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies; anti-CCP predicts erosive disease even when RF is negative 2
• Do not dismiss inflammatory arthritis if RF is negative—seronegative disease is common early, and anti-CCP testing remains essential 2
• Measure ESR and CRP; elevated acute-phase reactants predict higher risk of persistent or erosive disease 1, 2
• Screen antinuclear antibodies (ANA) to evaluate for connective-tissue disease 2
• Obtain complete blood count to identify infection or systemic inflammatory disease 2
• Perform urinalysis and baseline transaminases before potential DMARD therapy 2

Imaging Strategy

• Obtain plain radiographs of both hands (PA and lateral views) as baseline to detect early erosive changes 2
• Use power-Doppler ultrasound when physical exam is equivocal to confirm synovitis, detect effusion, and assess for tenosynovitis 2
• Clinical examination remains the primary diagnostic method; imaging confirms uncertain findings 1, 2
• Reserve MRI for cases where ultrasound is unavailable or diagnosis remains doubtful 2

Risk Stratification for Persistent/Erosive Disease

High-risk features include: 1, 2

• Multiple swollen and tender joints (polyarticular involvement)
• Elevated ESR and/or CRP
• Positive RF or anti-CCP antibodies
• Symmetric small-joint distribution
• Morning stiffness >30 minutes
• Early erosive changes on radiographs

Immediate Symptomatic Management

First-Line Pharmacotherapy

• Start NSAIDs: naproxen 500 mg twice daily or meloxicam 7.5–15 mg once daily for 4–6 weeks, using the lowest effective dose 1, 2
• Before prescribing NSAIDs, assess gastrointestinal, renal, and cardiovascular risk factors 1, 2
• NSAIDs can worsen renal perfusion in hypotensive patients; monitor blood pressure and renal function closely 2

Glucocorticoid Bridge Therapy

• If NSAIDs are ineffective or contraindicated, prescribe oral prednisone 10–20 mg daily for 2–4 weeks as bridge therapy 1, 2
• Limit total systemic glucocorticoid exposure to less than 6 months to reduce cumulative adverse effects 1, 2
• Consider intra-articular glucocorticoid injection into the most symptomatic joint for rapid localized relief 1, 2
• Chronic low-dose glucocorticoid therapy is strongly discouraged 2

Urgent Rheumatology Referral and DMARD Initiation

Referral Timing

• Arrange rheumatology follow-up within 6 weeks of symptom onset; do not wait for additional serologic results 1, 2
• The 6-week window is critical for early disease-modifying therapy 2

Early DMARD Strategy

• Patients at high risk for persistent arthritis should start methotrexate within 3 months of symptom onset (ideally by the rheumatologist) 1, 2
• Methotrexate is the anchor DMARD and forms the core of first-line treatment unless contraindicated 1, 2
• Initiating DMARDs within the 3-month "window of opportunity" prevents joint damage, improves long-term outcomes, and reduces morbidity 2
• Even if classification criteria for rheumatoid arthritis are not yet met, patients with risk factors for persistent disease should start DMARDs early 1

Monitoring After DMARD Initiation

• Disease activity should be evaluated every 1–3 months using tender/swollen joint counts, patient/physician global assessments, and ESR/CRP 1, 2
• The therapeutic target is clinical remission; treatment should be adjusted until this goal is achieved 1, 2

Critical Pitfalls to Avoid

• Do not postpone rheumatology referral while awaiting serologic results—the 6-week referral window is critical for optimal outcomes 1, 2
• Do not exclude inflammatory arthritis based on negative RF alone—seronegative disease is common early, and anti-CCP testing is essential 2
• Do not attribute polyarticular swelling to non-inflammatory causes (e.g., edema, lymphedema) without rheumatologic assessment, especially with morning stiffness >30 minutes 2
• Do not use NSAIDs without assessing cardiovascular, renal, and gastrointestinal risk—they can exacerbate hypotension and renal hypoperfusion 1, 2
• Do not delay DMARD therapy beyond 3 months in high-risk patients—early intervention prevents irreversible joint damage 1, 2

Prognosis and Patient Counseling

• Early DMARD therapy within 3 months is associated with significantly better outcomes regarding joint damage, physical function, and long-term disability 2
• Without early intervention, patients face increased risk of erosive disease, permanent joint deformity, and functional impairment 2
• Symptom relief often begins within weeks, but full disease control typically requires 3–6 months of DMARD therapy 2
• Lifelong treatment may be necessary to maintain remission 2